Compare THM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | THM | MLTX |
|---|---|---|
| Founded | 1978 | 2021 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.2M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | THM | MLTX |
|---|---|---|
| Price | $2.48 | $15.80 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.22 |
| AVG Volume (30 Days) | ★ 2.9M | 1.3M |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $5.95 |
| 52 Week High | $3.65 | $62.75 |
| Indicator | THM | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 53.84 |
| Support Level | $2.39 | $15.27 |
| Resistance Level | $2.79 | $16.15 |
| Average True Range (ATR) | 0.38 | 0.74 |
| MACD | -0.04 | -0.08 |
| Stochastic Oscillator | 18.44 | 66.14 |
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project namely the Livengood Gold Project. It is located in northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.